Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
- Russian-approved regimen: 0.15% intranasal solution, 250–500 mcg per dose, 2–3 times daily. Typical course 10–14 days.
Dose evidence detail — Selank
Detailed dose evidence documented for Selank in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
- Clinical studies used the approved intranasal regimen above.
Not established
What is not established
- Long-term efficacy beyond 14-day courses
- Safety and efficacy for off-label uses (social anxiety, PTSD, depression)
- Dose for non-approved routes (oral, subcutaneous, intravenous)
- Comparative effectiveness against SSRIs or other first-line anxiolytics